NASDAQ:DMPI - DelMar Pharmaceuticals, Inc.
$0.37
 $0.01
+1.78%
4:00PM EDT
2019-04-18
DelMar Pharmaceuticals, Inc., incorporated on June 24, 2009, is a clinical-stage drug development company. The Company focuses on the treatment of cancer. The Company is engaged in conducting clinical trials in the United States with its product candidate, VAL-083, as a treatment for glioblastoma multiforme (GBM), a form of brain cancer. VAL-083 is being evaluated in a Phase II clinical trial for the treatment of refractory GBM. In addition to its clinical development activities in the United States, the Company has obtained certain commercial rights to VAL-083 in China where it is approved as a chemotherapy for the treatment of chronic myelogenous leukemia (CML) and lung cancer. Its drug discovery research focuses on identifying validated clinical and commercial-stage compounds, and establishing a scientific rationale for development in orphan drug indications.VAL-083 represents a small molecule chemotherapeutic approved for the treatment of cancer. As of June 30, 2016, VAL-083 had been assessed in 42 Phase I and Phase II clinical trials sponsored by the National Cancer Institute (NCI) in the United States as a treatment against various cancers, including lung, brain, cervical, ovarian tumors and leukemia. Read more at  reuters.com
sector:  health care
industry:  biotechnology
the data below are updated and published after 9pm EDT each trading day
  DMPI     avg for
industry  
  avg for
sector  
42 stocks weight:  0. 97   199. 07   233. 87  
42 stocks rank:  3. 34 K 1. 43 K 1. 06 K
# analyst opinions:  1. 00   14. 48   14. 09  

quick ratio:  2. 93   5. 29   1. 92  
current ratio:  3. 17   5. 64   2. 40  

target price low:  0. 38   84. 50   115. 74  
target price avg:  0. 38   110. 73   137. 39  
target price high:  0. 38   136. 41   157. 80  
1-yr high:  1. 04   114. 11   138. 85  
last close:  0. 37   87. 56   116. 78  
50-day avg:  0. 38   95. 43   123. 53  
200-day avg:  0. 51   94. 13   121. 20  
1-yr low:  0. 29   72. 67   98. 41  
volume:  73. 17 K 2. 43 M 4. 85 M
50-day avg volume:  314. 69 K 2. 72 M 4. 97 M
200-day avg volume:  156. 67 K 2. 90 M 4. 58 M

1-day return:  2. 78 % -0. 40 % 0. 07 %
this week return:  5. 71 % -5. 72 % -4. 11 %
12-wk return:  -7. 50 % 1. 78 % -0. 04 %
52-wk return:  -66. 32 % 10. 81 % 14. 09 %

enterprise value (EV):  11. 40 M 51. 19 B 117. 96 B
market cap:  9. 31 M 43. 00 B 104. 52 B
total debt:  0. 00   12. 22 B 16. 66 B
net income (common):  -9. 24 M 2. 20 B 4. 21 B

shares outstanding:  25. 59 M 570. 91 M 1. 24 B
shares:  22. 83 M 571. 02 M 1. 23 B
shares short:  550. 17 K 9. 93 M 16. 79 M
shares short prior month:  528. 74 K 9. 96 M 16. 58 M
short ratio:  3. 02   5. 31   3. 30  
short % of float:  2. 62 % 5. 81 % 2. 61 %
total cash/share:  0. 14   11. 13   9. 30  
total cash:  3. 70 M 6. 70 B 7. 10 B
free cash flow:  -4. 96 M 3. 58 B 4. 74 B
operating cash flow:  -8. 40 M 4. 14 B 6. 32 B

book value:  -0. 13   12. 76   26. 84  
price/book:  -2. 87   3. 08   -1. 74  
operating margins:  0. 00 % -721. 97 % -88. 82 %
EBITDA margins:  0. 00 % 10. 94 % 22. 54 %
profit margins:  0. 00 % 7. 81 % 10. 60 %
gross margins:  0. 00 % 37. 02 % 55. 68 %

1-yr max volatility:  30. 92 % --- ---
1-yr mean volatility:  -0. 28 % 0. 03 % 0. 04 %

1-yr EPS:  -0. 40   2. 39   4. 08  
forward EPS:  -0. 54   3. 97   7. 14  
P/E:  -0. 93   13. 59   22. 83  
forward P/E:  -0. 65   -20. 05   14. 49  
PE/G:  0. 02   -1. 46   1. 68  
growth:  -49. 40 % 126. 81 % 29. 29 %
earnings high:  -0. 00   1. 02   1. 63  
earnings avg:  -0. 00   0. 76   1. 51  
earnings low:  -0. 00   0. 47   1. 39  
revenue high:  -0. 00   2. 68 B 10. 71 B
revenue avg:  -0. 00   2. 59 B 10. 49 B
revenue low:  -0. 00   2. 49 B 10. 25 B
return on assets:  -70. 52 % -2. 80 % 5. 29 %
return on equity:  -142. 90 % -18. 52 % 7. 38 %

beta (1yr vs S&P500):  1. 19   1. 24   0. 93  
sharpe (1yr):  -0. 90   0. 29   0. 60  

held % insiders:  7. 73 % 6. 38 % 3. 38 %
held % institutions:  7. 86 % 78. 60 % 68. 65 %

Research more with google or yahoo!
the data below are updated and published after 9pm EDT each trading day

2019-04-19 : DMPI
.     + 0.21 =          0.21 :: INITIAL WEIGHT
.   + 37.589 =        37.799 :: spline projection addition
.    x 1.432 =        54.129 :: industry recommendation factor
.    x 0.993 =        53.747 :: return on assets factor
.    x 0.986 =        52.979 :: return on equity factor
.    x 2.562 =       135.744 :: current ratio factor
.    x 1.232 =       167.283 :: quick ratio factor
.    x 1.154 =       193.002 :: short ratio factor
.    x 1.971 =       380.469 :: price-to-book factor
.    x 2.162 =       822.465 :: P/E weight
.    x 2.209 =      1816.791 :: PE/G factor
.    x 1.511 =       2745.43 :: beta factor
.    x 0.895 =      2457.793 :: sharpe factor
.    x 1.178 =      2894.128 :: target low factor
.     x 1.06 =      3067.659 :: target mean factor
.    x 1.018 =      3122.839 :: target high factor
.    x 1.312 =      4096.067 :: industry 2-weeks return factor
.    x 0.919 =      3764.724 :: overall "drift" factor
.    x 0.691 =        2600.7 :: largest single-day jump factor
.    x 0.059 =       154.712 :: low price factor
.      x 1.0 =       154.687 :: factor hist industry gain for week 15
.   cubeRoot =         5.368 :: reduced to standardize
.   - 25.992 =         0.967 :: add/subtract for performance
.                      0.967 :: FINAL WEIGHT for NASDAQ:DMPI


 


News feed RSS items generated from finance.google.com

News feed formatting by feed2js.org